OA09.03 Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)Ao Xiong, Chun Zhou, Xiaowei Dong et al.|Journal of Thoracic Oncology|2024Cited by 2